Zac Sniderman - Growth Drivers in the Microbiome Market24 Jun 2022 19:32
Zac Sniderman, Director of Business Development, North America, OptiBiotix Health Plc - Interviewed among others - 23 June 2022
https://wholefoodsmagazine.com/current-issue/growth-drivers-in-the-microbiome-market/
Extracts
Zac Sniderman, Director of Business Development, North America, OptiBiotix Health Plc: The microbiome—particularly in relation to gut health—is a major area of scientific research, which is providing exciting results. With healthcare transitioning from reactive to preventative, personalized nutrition is a key area for many microbiologists. However, as an individual’s microbiome is unique, pinpointing exactly what makes one person more susceptible to changes in their diet versus another is proving challenging.
Researchers are now beginning to profile the effect that certain medical conditions, such as Irritable Bowel Syndrome (IBS), IBD, and more, can have on the gut microbiome with machine-learning algorithms. Those with IBS, for example, can have completely different gut microbiota depending on whether they have symptoms of diarrhea or constipation. In addition, new research into antibiotics use also creates a major shift in the gut microbiome, particularly in otherwise healthy individuals, creating a prevalence of resistance genes. This is driving the need for natural alternatives instead of antibiotic treatments, especially for women who are susceptible to recurrent UTI infections.
Then, we have innovations beyond the traditional probiotics. While Lactobacillus and Bifidobacterium species are the most common strains used in probiotics today, there is also the rise of next-generation probiotics such as F. prausnitzii, used for its anti-inflammatory properties.
There is also research into how we can better profile the gut microbiome in response to dietary fiber. A study in China has proved that an ecological methodology could lead to the “rational design of nutritional strategies” for precision modulation of the gut microbiome. For instance, we now understand that those who consume a high-fiber diet are responding better to cancer treatments such as chemotherapy and immunotherapy..
When it comes to the microbiome, it’s the science and innovative treatments discovered that are driving sharp growth.
Natural probiotic strains like Lactobacillus plantarum LPLDL that have been clinically proven to aid in cholesterol management, while having a positive impact on the microbiome, can also be easily added by manufacturers to cheese and yogurts without additional side effects. Demand for these products is only growing and, at OptiBiotix, we see a bright future for food as medicine.
mol
Sign In
Follow the stocks
